Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02362373 · ClinicalTrials.gov registry record · Phase 4

Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users

A Phase 4 study, sponsored by Columbia University.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target

NCT02362373 is a Phase 4 study that has completed, run by Columbia University. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02362373, a Phase 4 study, has completed, sponsored by Columbia University.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target

Study Summary

The investigators will conduct a prospective, seven-month pilot study to explore pharmacokinetic (PK) and pharmacodynamic (PD) effects among women with epilepsy using the levonorgestrel intrauterine system (LNG IUS) for contraception. The investigators will enroll twenty women with well-controlled epilepsy maintained on stable anti-epileptic drugs (AED) therapy seeking the LNG IUS for contraception. The primary outcomes are AED levels and seizures before and after LNG IUS placement. Secondary outcomes include LNG levels, evidence of ovulation three weeks after insertion (serum progesterone \>3ng/ml), bleeding and spotting, endometrial thickness, continuation, satisfaction and adverse events (removals, expulsions, side effects). The investigators will conduct a baseline month assessment, insertion visit, and follow-up visits at 21 days, three months and six months.

Interventions

  • DRUG levonorgestrel IUS

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2011-08
Est. Completion 2014-01
Phase Phase 4

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT02362373

The ClinicalTrials.gov registry entry for NCT02362373 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which levonorgestrel IUS is the first listed.

NCT02362373 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02362373 about?

NCT02362373 is a clinical study titled "Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users". The investigators will conduct a prospective, seven-month pilot study to explore pharmacokinetic (PK) and pharmacodynamic (PD) effects among women with epilepsy using the levonorgestrel intrauterine system (LNG IUS) for contraception. The investigators will enroll twenty women with well-controlled e...

What is the current status of trial NCT02362373?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2011-08. Estimated completion is 2014-01.

What interventions are being tested in trial NCT02362373?

The interventions under investigation include: levonorgestrel IUS (DRUG).

Who is sponsoring clinical trial NCT02362373?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.